Skip Navigation

European Heart Journal 1999 20(23):1745-1751; doi:10.1053/euhj.1999.1697
Copyright © 1999 by the European Society of Cardiology.
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Santini, M
Right arrow Articles by Guido, V
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Santini, M
Right arrow Articles by Guido, V
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

The effect of atropine in vasovagal syncope induced by head-up tilt testing

M Santini, F Ammiratif1, F Colivicchi, G Gentilucci and V Guido

Heart Disease Department, S. Filippo Neri Hospital, Rome, Italy

Received March 2, 1999; accepted March 5, 1999

Abstract

Aims This single-blinded, randomized, placebo-controlled study was designed and undertaken to assess the efficacy of intravenous atropine administration on haemodynamic impairment induced by head-up tilt testing in patients with vasovagal syncope.

Methods and Results One hundred and thirteen consecutive patients (62 male and 51 female, mean age 46·3 years) with recurrent syncope, no evidence of cardiac, neurological or metabolic disease and a positive head-up tilt test were included in the study. Within 2 weeks of the first head-up tilt test all patients underwent a second tilt test. During this second test, all patients were randomized to receive a bolus of either atropine (0·02mg.kg–1) or placebo (isotonic saline solution). The administration of atropine or placebo was performed at the onset of the haemodynamic modifications (heart rate and/or blood pressure fall) in conjunction with typical vasovagal prodromal symptoms. Treatment was taken as effective when symptoms aborted and the test was completed. In 29 of 113 patients the second tilt test was negative and these patients were excluded from final data analysis. Forty-one patients received placebo, which was effective in nine cases (21·9%). Atropine was administered to 43 patients and was effective in 30 cases (69·7%, P<0·01 vs placebo). The effects of treatment were analysed further to consider the haemodynamic patterns of tilt-induced vasovagal reflex. In the cardio-inhibitory form, placebo was never effective (15 cases), while atropine was effective in 15 of 18 cases (83·3%, P<0·001 vs placebo). In the vasodepressor form, placebo was effective in nine of 26 patients (34·6%), while atropine was effective in 15 of 25 cases (60·0%, no significant difference vs placebo).

Conclusions Atropine is fully effective in the cardio-inhibitory form of tilt-induced vasovagal reflex, but is limited in the vasodepressor form.

Key Words: Vasovagal syncope, atropine, head-up tilt testing

f1 Correspondence: Dott. Fabrizio Ammirati, Dipartimento delle Malattie del Cuore, Ospedale S. Filippo Neri, Via Attilio Friggeri, 95, 00136, Roma, Italy.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
A. Raviele, F. Giada, and G. Gasparini
Efficacy of a patient-activated pharmacologic pump using phenylephrine as active drug and prodromal symptoms as a marker of imminent loss of consciousness to abort tilt-induced syncope
J. Am. Coll. Cardiol., January 18, 2005; 45(2): 320 - 321.
[Full Text] [PDF]


Home page
Eur Heart JHome page
H. Ector
Neurocardiogenic, vasovagal syncope
Eur. Heart J., December 1, 1999; 20(23): 1686 - 1687.
[PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.